Browsing ICR Divisions by title
Now showing items 4021-4040 of 4652
-
Systemic oncolytic adenovirus delivered in mesenchymal carrier cells modulate tumor infiltrating immune cells and tumor microenvironment in mice with neuroblastoma.
(Impact Journals, LLC, 2020-01-28)Celyvir (autologous mesenchymal cells -MSCs- that carry an oncolytic adenovirus) is a new therapeutic strategy for metastatic tumors developed by our research group over the last decade. There are limitations for studying ... -
Systemic Radiotherapy of Bone Metastases With Radionuclides.
(2021-02)Treatments of bone metastases using radionuclides are now well established in oncology. It is also a field that continues to develop. This article reviews the evidence base that led to the approval of strontium-89 and ... -
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature.
Background This observational, retrospective effort across Europe, US, Australia, and Asia aimed to assess the activity of systemic therapies in EHE, an ultra-rare sarcoma, marked by WWTR1-CAMTA1 or YAP1-TFE3 fusions.Methods ... -
Systemic therapy for early breast cancer in older adults: current status and prospects.
(LIPPINCOTT WILLIAMS & WILKINS, 2021-11-01)PURPOSE OF REVIEW: In this review, we describe the evidence on the efficacy and the safety of systemic treatments for the management of early breast cancer (EBC) in older individuals. RECENT FINDINGS: Chemotherapy has a ... -
Systemic Therapy for Hereditary Breast Cancers.
(W B SAUNDERS CO-ELSEVIER INC, 2023-02-01)Approximately 5% to 10% of all breast cancers are hereditary; many of which are caused by pathogenic variants in genes required for homologous recombination, including BRCA1 and BRCA2. Here we discuss systemic treatment ... -
Systemic therapy in elderly patients with advanced biliary tract cancer: Sub-analysis of ABC-02 and 10 other prospective studies.
(AMER SOC CLINICAL ONCOLOGY, 2016-02-01) -
Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials.
(2017-04-12)Background Outcomes in younger (<40 years) and elderly (≥70 years) patients with advanced biliary cancer (ABC) receiving palliative chemotherapy are unclear. This study assessed outcomes in those receiving monotherapy or ... -
Systemic therapy is effective in the management of leiomyomatosis
(MRE PRESS, 2022-06-14) -
Systemic Therapy of Common Tumours in Older Patients: Challenges and Opportunities. A Young International Society of Geriatric Oncology Review Paper.
(SPRINGER, 2020-07-28)PURPOSE OF REVIEW: Decision-making for systemic treatments in older patients with cancer is difficult because of concerns for decreased organ function, risk of toxicity, limited life expectancy due to comorbidities and the ... -
Systemic Treatment for Adults with Synovial Sarcoma.
(2018-03-07)Opinion statement Synovial sarcoma (SS) is a rare, yet highly malignant, type of soft tissue sarcoma (STS), for which survival has not improved significantly during the past years. In this review, we focus on systemic ... -
Systemic treatment in adult uterine sarcomas.
(2018-02)Uterine sarcomas (US) are rare mesenchymal tumours of the uterus and are divided mainly into uterine leiomyosarcoma (uLMS), low grade endometrial stromal sarcoma (LG-ESS), high grade endometrial stromal sarcoma (HG-ESS), ... -
Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma Network.
(ELSEVIER, 2022-06-01)BACKGROUND: Clear cell sarcoma (CCS) is a translocated aggressive malignancy with a high incidence of metastases and poor prognosis. There are few studies describing the activity of systemic therapy in CCS. We report a ... -
Systems biology of the motif-mediated cell cycle interactome
(Institute of Cancer Research (University Of London), 2024-05-09)The eukaryotic cell cycle is a tightly controlled series of events leading to cell division. It relies on a complex network of regulatory proteins, serving as checkpoints to oversee DNA replication and ensure orderly cell ... -
Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs.
(NATL ACAD SCIENCES, 2021-04-27)Cancer cells can survive chemotherapy-induced stress, but how they recover from it is not known. Using a temporal multiomics approach, we delineate the global mechanisms of proteotoxic stress resolution in multiple myeloma ... -
T-cell Prolymphocytic Leukemia.
(W B SAUNDERS CO-ELSEVIER INC, 2017-04-01)T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive T-cell malignancy. T-PLL can be distinguished from other lymphoid diseases by the evaluation and integration of clinical features, morphology, immunophenotyping, ... -
T2-adjusted computed diffusion-weighted imaging: A novel method to enhance tumour visualisation.
(PERGAMON-ELSEVIER SCIENCE LTD, 2016-12-01)PURPOSE: To introduce T2-adjusted computed DWI (T2-cDWI), a method that provides synthetic images at arbitrary b-values and echo times (TEs) that improve tissue contrast by removing or increasing T2 contrast in diffusion-weighted ... -
T2-Weighted 4D Magnetic Resonance Imaging for Application in Magnetic Resonance-Guided Radiotherapy Treatment Planning.
(LIPPINCOTT WILLIAMS & WILKINS, 2017-10-01)OBJECTIVES: The aim of this study was to develop and verify a method to obtain good temporal resolution T2-weighted 4-dimensional (4D-T2w) magnetic resonance imaging (MRI) by using motion information from T1-weighted 4D ... -
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer.
(DOVE MEDICAL PRESS LTD, 2021-03-08)Insertion mutations in exon 20 (Ex20ins) of the epidermal growth factor receptor (EGFR) gene are the largest class of EGFR mutations in non-small cell lung cancer (NSCLC) for which there are currently no approved targeted ... -
A tailored approach to horizon scanning for cancer medicines.
(ELSEVIER SCI LTD, 2023-12-01)BACKGROUND: Horizon scanning (HS) is the systematic identification of emerging therapies to inform policy and decision-makers. We developed an agile and tailored HS methodology that combined multi-criteria decision analysis ...